Olema Oncology (OLMA) Citigroup’s Biopharma Back to School Summit 2026 summary
Event summary combining transcript, slides, and related documents.
Citigroup’s Biopharma Back to School Summit 2026 summary
10 Sep, 2026Pipeline overview and clinical trial updates
Lead asset palazestrant is in phase III trials for ER-positive, HER2-negative breast cancer, with OPERA-01 (second/third-line monotherapy) fully enrolled and top-line data expected in Q1 2027.
OPERA-01 tests both ESR1 mutant and wild-type populations, aiming to show improved progression-free survival (PFS) over standard of care; phase II data showed median PFS of 7 months (mutant) and 5.5 months (wild-type).
OPERA-02, a first-line trial combining palazestrant with KISQALI, is enrolling well; timeline for readout is not yet communicated due to potential trial adjustments based on emerging control arm data.
Both trials are powered to detect benefits in distinct patient subsets, with statistical design allowing for positive outcomes in either or both populations.
Commercial opportunity for palazestrant is estimated at $5 billion (second/third-line) and over $10 billion (first-line) globally, with the U.S. representing the majority of revenue.
Market strategy and commercialization plans
U.S. launch for second/third-line indication will be self-promoted, requiring fewer than 100 field sales staff; commercial build-out has already begun.
Outside the U.S., regulatory filings will proceed, but a commercial partner will be sought, likely after phase III data is available.
Market research and hiring are underway to support a rapid ramp-up post-data readout, with a focus on maximizing U.S. market share.
Competitive landscape and differentiation
Palazestrant aims to differentiate by exceeding the two-month PFS improvement seen with competitors in the mutant setting and by achieving benefit in the wild-type population, where no agent has succeeded.
Phase II data for palazestrant included less favorable patient characteristics than OPERA-01, suggesting potential for even better outcomes in the phase III trial.
Control arm performance in first-line trials is improving over time, prompting possible adjustments in trial powering and patient enrollment criteria.
Latest events from Olema Oncology
- Q1 OPERA-01 data will shape a potential mid-2028 launch and broader treatment opportunity.OLMA
Stifel 2026 Healthcare Conference 2026 - OPERA-01 data in Q1 2027 will test palazestrant across both ESR1 subsets.OLMA
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical spending deepened losses, while cash runway is projected through mid-2028.OLMA
Q3 2026 - Phase III breast cancer trial readout for palazestrant expected Q1 2027; new combo data due next year.OLMA
H.C. Wainwright 28th Annual Global Investment Conference - Palazestrant and KAT6 programs offer strong differentiation and major market potential, with key data ahead.OLMA
Morgan Stanley 24th Annual Global Healthcare Conference - Net loss rose 44% to $63.2M in Q2 2026 as Phase 3 trial enrollment completed and cash reached $461M.OLMA
Q2 2026 - Pivotal trials and new combinations position the pipeline for major advances in breast cancer care.OLMA
Jefferies London Healthcare Conference 2025 - Phase III breast cancer data expected in fall; KAT6 combos and strong cash position support growth.OLMA
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Promising clinical progress and strategic trial updates position the pipeline for significant impact.OLMA
Jefferies Global Healthcare Conference 2026